In this article, we will delve into a detailed comparison between Reneo Pharmaceuticals and Hepion Pharmaceuticals. We will analyze various factors such as valuation, risk, profitability, and institutional ownership to provide you with a comprehensive understanding of these two medical companies.
Valuation and Risk
Reneo Pharmaceuticals and Hepion Pharmaceuticals differ significantly in terms of valuation and risk. Let's take a closer look at these factors:
Valuation:
Reneo Pharmaceuticals has a higher consensus price target of $32.78, suggesting a potential upside of 373.63%. On the other hand, Hepion Pharmaceuticals does not have available data for valuation.
Risk:
When it comes to risk and volatility, Reneo Pharmaceuticals has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. In contrast, Hepion Pharmaceuticals has a beta of 1.58, making its share price 58% more volatile than the S&P 500.
Considering these factors, it is important for investors to carefully evaluate the valuation and risk associated with each company before making investment decisions.
Profitability and Earnings
Profitability and earnings play a crucial role in evaluating the financial performance of pharmaceutical companies. Here's how Reneo Pharmaceuticals and Hepion Pharmaceuticals compare:
Profitability:
Both Reneo Pharmaceuticals and Hepion Pharmaceuticals have negative net margins. Reneo Pharmaceuticals has a return on equity of -62.07% and a return on assets of -55.55%, while Hepion Pharmaceuticals has a return on equity of -145.58% and a return on assets of -104.36%.
Earnings:
In terms of earnings, Reneo Pharmaceuticals has an earnings per share (EPS) of ($2.38) and a price/earnings ratio of -2.91. Hepion Pharmaceuticals does not have available data for EPS and price/earnings ratio.
These metrics highlight the financial performance of each company and provide insights into their profitability and earnings potential.
Institutional Ownership and Insider Holdings
Institutional ownership and insider holdings can provide valuable information about investor confidence and management's belief in the company's potential. Let's compare Reneo Pharmaceuticals and Hepion Pharmaceuticals:
Institutional Ownership:
Reneo Pharmaceuticals has a higher institutional ownership, with 85.0% of its shares owned by institutional investors. In contrast, Hepion Pharmaceuticals has only 13.5% of its shares owned by institutional investors.
Insider Holdings:
When it comes to insider holdings, 17.9% of Reneo Pharmaceuticals shares are owned by company insiders, while only 2.0% of Hepion Pharmaceuticals shares are owned by company insiders.
These ownership figures reflect the confidence of institutional investors and insiders in the respective companies.
Analyst Recommendations
Analyst recommendations can provide insights into market sentiment and expert opinions on the prospects of a company. Let's compare the analyst recommendations for Reneo Pharmaceuticals and Hepion Pharmaceuticals:
Reneo Pharmaceuticals has 3 buy ratings and a rating score of 3.00, while Hepion Pharmaceuticals has 2 buy ratings and a rating score of 3.00.
These recommendations indicate positive sentiment towards both companies, but it's important to conduct further research and analysis before making investment decisions.
Company Profiles
Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, which is in clinical development for genetic mitochondrial diseases.
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of drug therapy treatment for chronic liver diseases. Its lead product candidate is Rencofilstat, which has completed Phase 2a clinical trials for the treatment of non-alcoholic steatohepatitis (NASH).
These profiles provide an overview of the core focus and lead product candidates of each company, offering insights into their respective areas of expertise.